Guardant Health, Inc. $GH Shares Sold by MSH Capital Advisors LLC

MSH Capital Advisors LLC cut its stake in Guardant Health, Inc. (NASDAQ:GH) by 46.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,937 shares of the company’s stock after selling 5,916 shares during the period. MSH Capital Advisors LLC’s holdings in Guardant Health were worth $709,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after acquiring an additional 251,939 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Guardant Health by 26.1% in the third quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after acquiring an additional 606,368 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Guardant Health in the third quarter valued at approximately $114,421,000. Federated Hermes Inc. boosted its holdings in shares of Guardant Health by 21.2% in the third quarter. Federated Hermes Inc. now owns 1,776,369 shares of the company’s stock valued at $110,988,000 after acquiring an additional 310,931 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its holdings in shares of Guardant Health by 10.4% in the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the sale, the insider directly owned 60,034 shares in the company, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the sale, the insider owned 45,950 shares of the company’s stock, valued at $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 321,244 shares of company stock valued at $34,775,166 in the last ninety days. 5.60% of the stock is owned by company insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $119.85 on Wednesday. The stock has a market capitalization of $15.89 billion, a price-to-earnings ratio of -35.35 and a beta of 1.48. Guardant Health, Inc. has a 1-year low of $37.73 and a 1-year high of $121.01. The company has a 50 day moving average price of $92.53 and a 200 day moving average price of $99.26.

Analyst Ratings Changes

Several research firms have recently issued reports on GH. Evercore set a $110.00 price objective on shares of Guardant Health in a report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Stifel Nicolaus increased their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Wells Fargo & Company increased their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Finally, Citigroup increased their price objective on shares of Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $129.53.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.